[Epigenetic research progress of anti-tumor drugs]

Area of Science:

• Oncology
• Pharmacology
• Epigenetics

Background:

• Epigenetic abnormalities are linked to cancer development.
• Epigenetic modifications can alter the effectiveness and patient outcomes of anticancer therapies.
• Epigenetic factors influence drug absorption, distribution, metabolism, and excretion (pharmacokinetics).

Purpose of the Study:

• To analyze the relationship between DNA methylation, miRNA, and histone modification and their impact on antitumor drug efficacy.
• To explore the potential of drugs targeting epigenetic factors for cancer treatment.
• To promote the rational application of anticancer drugs and inspire the development of novel epigenetic drugs.

Main Methods:

• Literature review and analysis of existing research on epigenetics and anticancer drug effects.
• Examination of how DNA methylation, microRNA (miRNA), and histone modifications influence drug pharmacokinetics and pharmacodynamics.
• Synthesis of findings to connect epigenetic regulation with antitumor drug response.

Main Results:

• Epigenetic alterations significantly affect the pharmacokinetics and pharmacodynamics of anticancer agents.
• Specific epigenetic modifications, such as DNA methylation and histone changes, are associated with varying responses to chemotherapy.
• miRNA dysregulation also plays a crucial role in modulating sensitivity and resistance to cancer drugs.

Conclusions:

• Epigenetic mechanisms are critical determinants of anticancer drug efficacy and patient prognosis.
• Targeting epigenetic factors represents a promising strategy for developing novel anticancer therapies (epi-drugs).
• A deeper understanding of epigenetics will facilitate personalized cancer treatment and optimize the use of existing antitumor drugs.